title: Risk assessment strategies for nanoscale and fine-sized titanium dioxide particles: Recognizing hazard and exposure issues.
abstract: The basic tenets for assessing health risks posed by nanoparticles (NP) requires documentation of hazards and the corresponding exposures that may occur. Accordingly, this review describes the range and types of potential human exposures that may result from interactions with titanium dioxide (TiO2) particles or NP - either in the occupational/workplace environment, or in consumer products, including food materials and cosmetics. Each of those applications has a predominant route of exposure. Very little is known about the human impact potential from environmental exposures to NP - thus this particular issue will not be discussed further. In the workplace or occupational setting inhalation exposure predominates. Experimental toxicity studies demonstrate low hazards in particle-exposed rats. Only at chronic overload exposures do rats develop forms of lung pathology. These findings are not supported by multiple epidemiology studies in heavily-exposed TiO2 workers which demonstrate a lack of correlation between chronic particle exposures and adverse health outcomes including lung cancer and noncancerous chronic respiratory effects. Cosmetics and sunscreens represent the major application of dermal exposures to TiO2 particles. Experimental dermal studies indicate a lack of penetration of particles beyond the epidermis with no consequent health risks. Oral exposures to ingested TiO2 particles in food occur via passage through the gastrointestinal tract (GIT), with studies indicating negligible uptake of particles into the bloodstream of humans or rats with subsequent excretion through the feces. In addition, standardized guideline-mandated subchronic oral toxicity studies in rats demonstrate very low toxicity effects with NOAELs of >1000 mg/kg bw/day. Additional issues which are summarized in detail in this review are: 1) Methodologies for implementing the Nano Risk Framework - a process for ensuring the responsible development of products containing nanoscale materials; and 2) Safe-handling of nanomaterials in the laboratory.
authors.affiliation: Chemours Company, Wilmington, DE, USA. Electronic address: david.b.warheit@chemours.com.
authors.forename: David B
authors.initials: DB
authors.lastname: Warheit
authors.affiliation: DuPont Haskell Global Centers for Health and Environmental Sciences, Newark, DE, USA.
authors.forename: E Maria
authors.initials: EM
authors.lastname: Donner
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000818:Animals; D003257:Consumer Product Safety; D004781:Environmental Exposure / Q000009:adverse effects; D004785:Environmental Pollutants / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D017408:Guidelines as Topic; D006801:Humans; D019570:Inhalation Exposure / Q000009:adverse effects; D053768:Metal Nanoparticles / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D016273:Occupational Exposure / Q000009:adverse effects; D010316:Particle Size; D018570:Risk Assessment / Q000379:methods* / Q000639:trends; D014025:Titanium / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D018675:Toxicity Tests / Q000379:methods / Q000592:standards
chemical_list: D004785:Environmental Pollutants; C009495:titanium dioxide; D014025:Titanium
keywords: Dermal toxicity; Nano risk framework; Nanomaterials; Oral toxicity; Pulmonary toxicity; Risk assessment; Routes of exposure; Titanium dioxide